China National Accord Medicines Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
China National Accord Medicines Stock Forecast and Price Target
The average price target for China National Accord Medicines's stock lately set by several renowned analysts is ¥40.00, which would result in a potential upside of approximately 13.86% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of ¥48.00 and a low estimate of ¥25.00. If you want to invest in 000028 stock, you might also want to take a look at how its competitors are doing.
13.86% Upside
China National Accord Medicines Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, China National Accord Medicines's Price has gone down from ¥36.43 to ¥0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach ¥49.76 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 603939 Stock Forecast | Yifeng Pharmacy Chain | Buy |
18
|
¥43.94 | Buy/Sell | ¥47.67 | 19.66% |
| 603233 Stock Forecast | DaShenLin Pharmaceutical Group | Buy |
18
|
¥21.78 | Buy/Sell | ¥34.94 | 55.19% |
| 603883 Stock Forecast | LBX Pharmacy Chain Joint Stock | Outperform |
18
|
¥33.47 | Buy/Sell | ¥39.56 | 23.16% |
| 000503 Stock Forecast | China Reform Health Management... | - |
10
|
¥9.26 | Buy/Sell | ¥0.00 | -100.00% |
| 002727 Stock Forecast | Yixintang Pharmaceutical Group | Outperform |
16
|
¥21.08 | Buy/Sell | ¥29.95 | 10.10% |
China National Accord Medicines Revenue Forecast for 2023 - 2025 - 2030
China National Accord Medicines's Revenue has seen growth In the last three years, going from ¥59.65B to ¥75.48B – a gain of 26.54% In the next year, analysts believe that Revenue will reach ¥86.70B – an increase of 14.87%. For the next seven years, the forecast is forRevenue to grow by 16.73%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600833 Stock Forecast | Shanghai No.1 Pharmacy | - |
14
|
¥11.20 | Buy/Sell | ¥0.00 | -100.00% |
| 000593 Stock Forecast | Delong Composite Energy Group | - |
11
|
¥5.39 | Buy/Sell | ¥14.44 | -100.00% |
| MDCE Stock Forecast | Medical Care Technologies | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
.jpg)
China National Accord Medicines Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, China National Accord Medicines's Dividend per Share has fallen from ¥0.80 to ¥0.68 – a 15.00% decrease. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach ¥0.85 – an increase of 25.00%. Over the next seven years, experts anticipate that Dividend per Share growth for China National Accord Medicines will be 24.37%.
China National Accord Medicines EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, China National Accord Medicines's EBITDA has increased by 21.83%, going from ¥2.11B to ¥2.57B. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach ¥3.30B – an increase of 28.80%. The China National Accord Medicines forecast is for EBITDA to reach ¥3.39B or grow by 32.05%.
China National Accord Medicines EBIT Forecast for 2023 - 2025 - 2030
In the last three years, China National Accord Medicines's EBIT has grown, increasing from ¥1.94B to ¥2.35B – an increase of 21.10%. For next year, the 5 analysts predict EBIT of ¥2.91B, which would mean an increase of 23.90%. Over the next seven years, the pros' prediction is EBITof ¥3.05B, which would mean a seven-year growth forecast of 29.98%.
China National Accord Medicines EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, China National Accord Medicines's EPS has gone down from ¥2.46 to ¥0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach ¥3.36 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
Site Navigation
.jpg)